13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001583977
Total reported value
$2.0B
$2.0B
42 檔
32.1%
The Q1 2025 SEC filing reveals that Cormorant Asset Management, LP held a total portfolio value of $2.0B, covering 42 public equity positions.
In Q1 2025, Cormorant Asset Management, LP adopted a defensive or profit-taking posture, trimming 3 positions and completely liquidating 90 holdings to manage risk exposure.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | MLTX | Moonlake Immunotherapeutics | Stock-Other | 24.95% | -0.99% | — | |
| 2 | EWTX | Edgewise Therapeutics Inc | Stock-Other | 6.79% | +0.07% | +20.42% | |
| 3 | BBIO | Bridgebio Pharma Inc | Stock-Healthcare | 5.20% | -1.07% | +25.00% | |
| 4 | ACLXGBX | Arcellx Inc | Stock-Other | 5.18% | — | -19.23% | |
| 5 | PRAX | Praxis Precision Medicines I | Stock-Other | 4.97% | -3.35% | +3.06% | |
| 6 | NAMS | NewAmsterdam Pharma Company N.V. | Stock-Other | 4.73% | -0.66% | -5.38% | |
| 7 | JANX | Janux Therapeutics Inc | Stock-Other | 4.36% | — | +2.38% | |
| 8 | EYPT | Eyepoint Inc | Stock-Other | 3.39% | -0.22% | — | |
| 9 | INSM | Insmed Inc | Stock-Healthcare | 3.01% | -1.15% | -19.23% | |
| 10 | DRUG | Bright Minds Biosciences Inc | Stock-Other | 2.87% | -0.64% | — | |
| 11 | ✓ | Helix Acquisition CORP Ii | Stock-Other | 2.47% | — | — | |
| 12 | 260 | Centessa Pharmaceuticals-adr | Stock-Other | 2.45% | -2.09% | EXIT | |
| 13 | ✓ | Merus N V | Stock-Other | 2.34% | — | — | |
| 14 | RAPP | Rapport Therapeutics Inc | Stock-Other | 2.22% | +1.02% | — | |
| 15 | AXSM | Axsome Therapeutics Inc | Stock-Healthcare | 2.19% | -0.42% | EXIT | |
| 16 | PHVS | Pharvaris N.V. | Stock-Other | 1.73% | -0.09% | — | |
| 17 | GHRS | GH Research PLC | Stock-Other | 1.67% | — | +238.84% | |
| 18 | ARQT | Arcutis Biotherapeutics Inc | Stock-Other | 1.59% | -0.29% | -26.03% | |
| 19 | TARS | Tarsus Pharmaceuticals Inc | Stock-Other | 1.55% | -0.47% | -20.00% | |
| 20 | SPRY | Ars Pharmaceuticals Inc | Stock-Other | 1.51% | — | +220.00% | |
| 21 | CRNX | Crinetics Pharmaceuticals In | Stock-Other | 1.51% | -0.22% | -40.00% | |
| 22 | CGON | Cg Oncology Inc | Stock-Other | 1.43% | — | — | |
| 23 | CRGX | Cargo Therapeutics Inc | Stock-Other | 1.03% | — | +185.93% | |
| 24 | ABVX | Abivax Sa-adr | Stock-Other | 1.00% | +0.36% | — | |
| 25 | ALMS | Alumis Inc | Stock-Other | 0.99% | +0.37% | — | |
| 26 | CRBP | Corbus Pharmaceuticals Holdi | Stock-Other | 0.95% | +0.02% | — | |
| 27 | RNAGBP | Avidity Biosciences Inc | Stock-Other | 0.89% | — | -61.90% | |
| 28 | ✓ | Stock-Other | 0.82% | — | — | ||
| 29 | ✓ | Engene Holdings Inc | Stock-Other | 0.78% | — | — | |
| 30 | BIOA | Bioage Labs Inc | Stock-Other | 0.74% | +0.46% | — | |
| 31 | RYTM | Rhythm Pharmaceuticals Inc | Stock-Other | 0.60% | — | -62.50% | |
| 32 | OKUR | Onkure Therapeutics Inc-a | Stock-Other | 0.59% | — | — | |
| 33 | BMEA | Biomea Fusion Inc | Stock-Other | 0.57% | — | — | |
| 34 | KRRO | Korro Bio Inc | Stock-Other | 0.50% | — | — | |
| 35 | PCVX | Vaxcyte Inc | Stock-Other | 0.50% | -0.14% | -58.82% | |
| 36 | AARD | Aardvark Therapeutics Inc | Stock-Other | 0.45% | — | — | |
| 37 | MBX | Mbx Biosciences Inc | Stock-Other | 0.39% | -0.12% | — | |
| 38 | ELVN | Enliven Therapeutics Inc | Stock-Other | 0.37% | +0.39% | NEW | |
| 39 | PLRX | Pliant Therapeutics Inc | Stock-Other | 0.30% | — | — | |
| 40 | KALAEUR | Kala Bio Inc | Stock-Other | 0.26% | — | — | |
| 41 | STOK | Stoke Therapeutics Inc | Stock-Other | 0.13% | — | — | |
| 42 | BHVN | Biohaven Ltd. | Stock-Other | 0.02% | +1.24% | -81.99% |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | EWTX | Edgewise Therapeutics Inc | +4.5% | +20.42% | Add |
| 2 | INSM | Insmed Inc | +2.8% | -19.23% | Add |
| 3 | ✓ | Merus N V | +2.1% | — | Add |
| 4 | 260 | Centessa Pharmaceuticals-adr | +1.4% | -11.71% | Add |
| 5 | BBIO | Bridgebio Pharma Inc | +1.3% | +25.00% | Add |
| 6 | PHVS | Pharvaris N.V. | +1.3% | — | Add |
| 7 | SPRY | Ars Pharmaceuticals Inc | +1.3% | +220.00% | Add |
| 8 | GHRS | GH Research PLC | +1.2% | +238.84% | Add |
| 9 | TARS | Tarsus Pharmaceuticals Inc | +0.1% | -20.00% | Trim |
| 10 | PLRX | Pliant Therapeutics Inc | -0.2% | — | Add |
| 11 | RNAGBP | Avidity Biosciences Inc | -1% | -61.90% | Trim |
| 12 | BMEA | Biomea Fusion Inc | -1.1% | — | Add |
| 13 | STOK | Stoke Therapeutics Inc | -1.3% | — | Trim |
| 14 | MLTX | Moonlake Immunotherapeutics | — | NEW | New buy |
| 15 | TPB | Turning Point Brands, Inc. | — | EXIT | Sold out |
| 16 | IWM | Ishares Russell 2000 ETF | — | EXIT | Sold out |
| 17 | AVIR | Atea Pharmaceuticals Inc | — | EXIT | Sold out |
| 18 | ✓ | Forma Therapeutics Holdings | — | EXIT | Sold out |
| 19 | DSGN | Design Therapeutics Inc | — | EXIT | Sold out |
| 20 | RVMD | Revolution Medicines Inc | — | EXIT | Sold out |
| 21 | OLMA | Olema Pharmaceuticals Inc | — | EXIT | Sold out |
| 22 | BCABGBP | Bioatla Inc | — | EXIT | Sold out |
| 23 | GLUE | Monte Rosa Therapeutics Inc | — | EXIT | Sold out |
| 24 | ARKG | Ark Genomic Revolution ETF | — | EXIT | Sold out |
| 25 | ACLXGBX | Arcellx Inc | — | NEW | New buy |
| 26 | PRAX | Praxis Precision Medicines I | — | NEW | New buy |
| 27 | ARKK | Ark Innovation ETF | — | EXIT | Sold out |
| 28 | NAMS | NewAmsterdam Pharma Company N.V. | — | NEW | New buy |
| 29 | JANX | Janux Therapeutics Inc | — | NEW | New buy |
| 30 | APLSUSD | Apellis Pharmaceuticals Inc | — | EXIT | Sold out |
| 31 | ALXO | Alx Oncology Holdings Inc | — | EXIT | Sold out |
| 32 | ✓ | — | EXIT | Sold out | |
| 33 | ZYMEUSD | Zymeworks Inc | — | EXIT | Sold out |
| 34 | EYPT | Eyepoint Inc | — | NEW | New buy |
| 35 | ✓ | — | EXIT | Sold out | |
| 36 | ✓ | — | EXIT | Sold out | |
| 37 | RCKT | Rocket Pharmaceuticals Inc | — | EXIT | Sold out |
| 38 | ✓ | Verve Therapeutics Inc | — | EXIT | Sold out |
| 39 | ✓ | Rain Oncology Inc Com | — | EXIT | Sold out |
| 40 | DRUG | Bright Minds Biosciences Inc | — | NEW | New buy |
| 41 | ACRS | Aclaris Therapeutics Inc | — | EXIT | Sold out |
| 42 | ✓ | Helix Acquisition CORP Ii | — | NEW | New buy |
| 43 | OMER | Omeros CORP | — | EXIT | Sold out |
| 44 | RAPP | Rapport Therapeutics Inc | — | NEW | New buy |
| 45 | AXSM | Axsome Therapeutics Inc | — | NEW | New buy |
| 46 | MRTXEUR | Mirati Therapeutics Inc | — | EXIT | Sold out |
| 47 | YMABUSD | Y-mabs Therapeutics Inc | — | EXIT | Sold out |
| 48 | AGENEUR | Agenus Inc | — | EXIT | Sold out |
| 49 | ✓ | Elevation Oncology Inc | — | EXIT | Sold out |
| 50 | ✓ | Vectivbio Holding | — | EXIT | Sold out |
According to official SEC Form 13F filings, Cormorant Asset Management, LP reported a total U.S. public equity portfolio value of $2.0B across 42 disclosed positions in Q1 2025.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including MLTX, EWTX, BBIO) accounted for 32.1% of total reported equity market value during Q1 2025.
Top New Position Initiated
MLTX
市值: $331.9M
Top Position Liquidated / Trimmed
TPB
前期市值: $237.0M
During Q1 2025, Cormorant Asset Management, LP's top holdings by market value included MLTX (24.9%)、EWTX (6.8%)、BBIO (5.2%). The largest single position, MLTX, represented 24.9% of total portfolio value.
In Q1 2025, Cormorant Asset Management, LP made 132 total portfolio adjustments, initiating 29 new buys, adding to 10 positions, trimming 3 holdings, and fully liquidating 90 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.